Advisory Committee on Immunization Practices (ACIP): Mumps Work Group

Kelly L. Moore MD, MPH
Director, Tennessee Immunization Program
Chair, Mumps ACIP Work Group

ACIP Meeting
June 20, 2018
Mumps Work Group: Terms of Reference

Objective
• Evaluate and propose policy options to prevent or control mumps outbreaks in the United States

Activities
• Review epidemiology of mumps in the 2-dose vaccine era, including the international experience
• Review available evidence on duration of immunity for mumps after 2 doses of MMR and other risk factors for vaccine failure
• Review available evidence on impact of a 3rd dose of MMR vaccine for mumps outbreak control
• Evaluate programmatic implications and cost of various policy options for a 3rd dose of MMR vaccine to prevent or control mumps outbreaks
Mumps Work Group: Members

ACIP
Kelly Moore, Chair
Paul Hunter
Cynthia Pellegrini
Jose Romero

Ex Officio Members & Liaison Representatives
Carol Baker (IDSA)
Chas DeBolt (CSTE)
Shalini Desai (NACI)
Susan Even (ACHA)
Amy Groom (IHS)
Melissa Martinez (AAFP)
Dawn Nolt (AAP/COID)
Steven Rubin (FDA/CBER)
Jane Zucker (AIM)

Consultants
Huong McLean
Patricia Quinlisk
Jane Seward
Stanley Plotkin*

CDC
Mona Marin, CDC lead
Tracy Ayers
Nakia Clemmons
Carole Hickman
Manisha Patel
Paul Rota
Janell Routh
Melinda Wharton
Patricia Wodi
Fangjun Zhou
Adria Lee
Mariel Marlow

*expert consultant on scientific discussions
# Mumps Work Group: Activities and Outcomes, February 2017-June 2018

<table>
<thead>
<tr>
<th>Timeline</th>
<th>Activities</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>March-October 2017</td>
<td>Evidence assessment</td>
<td>October 2017</td>
</tr>
<tr>
<td>• 13 WG calls</td>
<td>• Mumps epidemiology</td>
<td>• Proposed WG recommendations</td>
</tr>
<tr>
<td>• 4 online surveys</td>
<td>• 2-dose MMR vaccine impact</td>
<td>• ACIP recommended use of a 3&lt;sup&gt;rd&lt;/sup&gt; dose of mumps-virus containing vaccine for persons in the groups identified at increased risk for mumps during an outbreak</td>
</tr>
<tr>
<td></td>
<td>• Data on and experience with 3&lt;sup&gt;rd&lt;/sup&gt; dose MMR vaccine use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Critical review of published and unpublished data regarding mumps outbreaks</td>
<td></td>
</tr>
<tr>
<td>January-June 2018</td>
<td>Technical consultation, discussion and feedback for the CDC guidance</td>
<td>June 2018</td>
</tr>
<tr>
<td>• 4 WG calls</td>
<td>for use of a 3&lt;sup&gt;rd&lt;/sup&gt; dose of MMR vaccine during mumps outbreaks</td>
<td>• Proposed CDC guidance for use of a 3&lt;sup&gt;rd&lt;/sup&gt; dose of MMR vaccine during mumps outbreaks presented to ACIP</td>
</tr>
<tr>
<td>• 1 online survey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3 rounds of document review</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Mumps Work Group: Next Steps

- Mumps ACIP WG accomplished its terms of reference
- Hiatus of WG activities
  - CDC will continue to monitor mumps epidemiology in the US and new scientific evidence that can inform better control of mumps
    - WG calls as needed as new information becomes available